Promoters of BRCA testing under insurance coverage for non-metastatic breast cancer patients in Japan: a retrospective cohort study

Taji, Tomoe; Odan, Nina; Kataoka, Yuki; IKEDA, MAKO; Yamaguchi, Ai; Suzuki, Eiji; Suwa, Hirofumi

doi:10.1007/s12282-022-01424-3

Cited by 1 publication

(1 citation statement)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Based on search of literature, the treatment for early stage or non-metastatic MBCs includes the following 127 ‐ 130 : Surgery Radiation therapy Chemotherapy Hormonal therapy Earlier, Scott-Conner 106 and his colleagues have also reported that men with BC would also be treated with: Modified radical mastectomy Axillary lymph node dissection Sentinel node biopsy Beside which, the other options may include breast conservation or nipple-sparing of skin-sparing mastectomies. With respect to the limited number of studies and data for the use of chemotherapy to treat MBC, clinicians would prefer to assess the typical factors that has similar features of the FBC with early-stage of the disease.…”

Section: Ductal Carcinoma In Situ (Dcis)mentioning

confidence: 99%

Male Breast Cancer: Current Scenario and Future Perspectives

Chidambaram,

Prabhakaran,

Sivasamy

et al. 2024

Technol Cancer Res Treat

View full text Add to dashboard Cite

Male breast cancer (MBC), one of the rare types of cancer among men where the global incidence rate is 1.8% of all breast cancers cases with a yearly increase in a pace of 1.1%. Since the last 10 years, the incidence has been increased from 7.2% to 10.3% and the mortality rate was decreased from 11% to 3.8%. Nevertheless, the rate of diagnoses has been expected to be around 2.6% in the near future, still there is a great lack in studies to characterize the MBC including the developed countries. Based on our search, it is evidenced from the literature that the number of risk factors for the cause of MBC are significant, which includes the increase in age, family genetic history, mutations in specific genes due to various environmental impacts, hormonal imbalance and unregulated expression receptors for specific hormones of high levels of estrogen or androgen receptors compared to females. MBCs are broadly classified into ductal and lobular carcinomas with further sub-types, with some of the symptoms including a lump or swelling in the breast, redness of flaky skin in the breast, irritation and nipple discharge that is similar to the female breast cancer (FBC). The most common diagnostic tools currently in use are the ultrasound guided sonography, mammography, and biopsies. Treatment modalities for MBC include surgery, radiotherapy, chemotherapy, hormonal therapy, and targeted therapies. However, the guidelines followed for the diagnosis and treatment modalities of MBC are mostly based on FBC that is due to the lack of prospective studies related to MBC. However, there are distinct clinical and molecular features of MBC, it is a need to develop different clinical methods with more multinational approaches to help oncologist to improve care for MBC patients.

show abstract